Objective To explore the risk factors of postoperative recurrence of benign meningioma. Methods A total of 241 cases of postoperative patients with benign meningiomas in Affiliated Hospital of Chengde Medical University were selected as the research object (using a retrospective method), the selection time is from January 2018 to March 2021, and all the patients' clinical basic data were sorted and analyzed. According to whether the recurrence within 1 year after surgery, patients were divided into no recurrence group (212 cases) and recurrence group (29 cases). Single factor analysis was applied to analyze the clinical data of the two groups, and multivariate Logistic regression analysis was applied to analyze the statistically significant factors and screen out the independent risk factors for postoperative recurrence of benign meningioma. Results Among the postoperative patients with benign meningiomas, the proportion of patients with tumor site (cerebral falx or venous sinus), maximum tumor diameter>5cm, partial tumor resection, unclear tumor boundary, histopathological endothelial type/fibroblast and Ki-67 expression≥8% in the recurrence group was higher than that in the non-recurrence group, and the difference was statistically significant (P<0.05). There was no statistically significant difference in gender, age, tumor shape, peritumoral edema, meningeal tail sign, FASN expression and PCNA expression between the two groups (P>0.05). Tumor location (cerebral falx or venous sinus), tumor maximum diameter>5cm, partial tumor resection, unclear tumor boundary, histopathological endothelial type/fibroblast and Ki-67 expression≥8% were all risk factors for recurrence of benign meningioma postoperative patients. The differences were statistically significant (P<0.05). Conclusion Tumor site (cerebral falx or venous sinus), maximum tumor diameter>5cm, partial tumor resection, unclear tumor boundary, histopathological endothelial type/fibroblast and Ki-67 expression≥8% are all risk factors for recurrence of patients with benign meningioma after operation. Therefore, corresponding clinical measures can be taken to prevent and treat patients with benign meningioma after operation to improve their prognosis and reduce recurrence rate.

Objective: To investigate the expression and clinical significance of adisintegrin and metalloprotease-17 (ADAM17) and epidermal growth factor receptor(EGFR) in endometrial carcinoma. Methods: Immunohistochemical staining was used to detect the ADAM17 and EGFR expression in 20 cases of normal endometrium, 20 cases of atypical hyperplasia endometrium and 50 cases of endometrial carcinoma. Results: The positive expression rate of ADAM17 and EGFR in endometrial carcinoma were all obviously higher than normal endometrium and atypical hyperplasia endometrium (P<0.01). In endometrial carcinoma, the expression of ADAM17 and EGFR were related to muscular infiltration depth and lymph node metastasis (P<0.05), but not related to age and whether menopause (P>0.05). In endometrial carcinoma, the expression of ADAM17 was positively correlated to EGFR (r=0.691, P<0.01). Conclusions: ADAM17 and EGFR may play important role in development and metastasis of endometrial carcinoma.

Objective: To investigate the effects of sericin on cell viability and insulin secretion of streptozotocin (STZ)injured rats’ insulinoma INS-1 cells. Methods: The INS-1 cells were randomly divided into normal group, STZ group and sericin group. The cells in STZ group were cultured with STZ(10mmol/L) for 24h; the cells in sericin group were cultured with STZ(10mmol/L) and sericin (300μg/L) at the same time for 24h. The general state of INS-1 cells was observed by optical inverted microscope, MMT to detect the cell viability of INS-1 cells and ELISA to detect the insulin content in supernate. Results: Compared with normal group, the cell viability and insulin content in supernate of INS-1 cells decreased obviously (P<0.05); After treating with sericin (300μg/L) , the cell viability and insulin content in supernate of INS-1 cells increased obviously (P<0.05). Conclusions: Sericin can promote insulin secretion by enhancing the cell viability of STZ injured rats ’insulinoma INS-1 cells.